Soleno Therapeutics (NASDAQ: SLNO) shares are experiencing a dramatic pre-market plunge of 21.39% on Wednesday, continuing a downward trend that began in after-hours trading on Tuesday. This significant drop comes as a surprise to many investors, given the company's strong third-quarter 2025 financial results released late Tuesday.

The biotech firm, focused on developing treatments for rare diseases, reported impressive numbers for the quarter ended September 30, 2025: - Revenue of $66.0 million - Net income of $26.0 million, or $0.47 per diluted share - Operating income of $22.1 million These results significantly surpassed analyst expectations, with earnings per share of $0.47 beating the mean analyst forecast of $0.05.

Despite these positive financials and the successful U.S. launch of VYKAT XR, Soleno's treatment for hyperphagia in patients with Prader-Willi syndrome (PWS), investors seem to be reacting negatively. The company reported 1,043 patient start forms received since the drug's approval in March 2025, with 764 active patients on the drug as of September 30. However, this apparent success has not translated into stock price gains. Possible explanations for the sell-off include valuation concerns, worries about future growth potential, competitive landscape shifts, or profit-taking by investors. As the market continues to digest the full earnings report and management's commentary, it remains to be seen whether this pre-market plunge will persist or if the stock will recover based on its strong fundamentals.